NCT07382739

A Phase 2 Study of Radiotherapy-induced Immune Priming to Enhance Elranatamab (Elra) in Relapsed Refractory Multiple Myeloma (RRMM) With Extramedullary Disease (EMD) and Paramedullary Disease (PMD) "PRIME-EMD-PMD"

• Status: Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 34 (estimated)
• Sponsor: M.D. Anderson Cancer Center · Academic / Other
• Sex: All
• Age: —
• Healthy volunteers: Not accepted

Summary

To learn if low doses of radiation therapy can help the drug elranatamab enhance the killing effect of the cancer cells.

Detailed description

Primary Objectives To evaluate the efficacy of RT-induced immune priming to enhance Elranatamab (Elra) in RRMM with EMD or PMD as measured by overall response rate (ORR) at 3 months Secondary Objectives To describe adverse events (AEs). To determine time to next treatment (TTNT). To evaluate progression-free survival (PFS). To determine overall survival (OS). To estimate quality of life (QOL). To assess local control to the irradiated lesions To determine differences in response in patients with EMD vs PMD To determine differences in response in patients High Risk (HR) vs Standard Risk (SR) disease

Conditions

• Phase 2
• Radiotherapy-Induced Immune Priming
• Elranatamab
• Relapsed Refractory Multiple Myeloma (RRMM)
• Extramedullary Disease in Multiple Myeloma
• Paramedullary Disease
• PMD

Interventions

Type	Name	Description
DRUG	Elranatamab	Given by IV

Timeline

• Start date: 2026-03-31
• Primary completion: 2028-12-31
• Completion: 2030-12-31
• First posted: 2026-02-03
• Last updated: 2026-04-14

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study